Effect of Drotrecogin alfa (activated) on platelet receptor expression in vitro

Platelets

Volumn 18, Issue 5, 2007, Pages 373-378

  Schuerholz, Tobias ^a   Friedrich, Lars ^b   Marx, Gernot ^a   Kornau, Ines ^b   Sümpelmann, Robert ^b   Scheinichen, Dirk ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Drug effects; Hemostasis; Platelet activation; Platelet membrane glycoproteins; Sepsis

Indexed keywords

BIOLOGICAL MARKER; DROTRECOGIN; GLYCOPROTEIN; PADGEM PROTEIN; THROMBOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; GRANULOCYTE; HEMOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE;

ADULT; AGED; ANTI-INFECTIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PLATELETS; GENE EXPRESSION REGULATION; GRANULOCYTES; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET ACTIVATION; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; SEVERITY OF ILLNESS INDEX; THROMBOCYTOPENIA;

EID: 34547229869     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100601100788     Document Type: Article

References (26)

1. Akca S, Haji-Michael P, de Mendonca A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med 2002;4:753-756.
2. Stephan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest 1999;5:1363-1370.
3. Vincent JL, Yagushi A, Pradier O. Platelet function in sepsis. Crit Care Med 2002;5 Suppl:S313-S317.
4. Gawaz M, Dickfeld T, Bogner C, Fateh-Moghadam S, Neumann FJ. Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997;4:379-385.
5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;10:699-709.
6. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001;7 Suppl:S48-S51. discussion 51-42.
7. Morris PE, Hite RD, Ohl C. Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C. Bio Drugs 2002;6:403-417.
8. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;14:11199-11203.
9. Lyseng-Williamson KA, Perry CM. Drotrecogin alfa (activated). Drugs 2002;4:617-630; discussion 631-612.
10. Kaiser B, Jeske W, Hoppensteadt DH, Walenga JM, Drohan W, Fareed J. In vitro studies on the effect of activated protein C on platelet activation and thrombin generation. Thromb Res 1997;2:197-204.
11. Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 2004;1:41-49.
12. Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003;2:155-163.
13. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;6:1644-1655.
14. Pearson ES, Please NW. Relation between the shape of population distribution and the robustness of four simple test statistics. Biometrika 1975;62:223-241.
15. Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003;1 Suppl:S85-S93.
16. Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005;10:2266-2277.
17. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;13:1332-1341.
18. Komoriya K, Inoue K, Takahashi K, Suzuki K. Inhibitory effect of activated protein C on platelet aggregation induced by the prothrombin- converting reaction. Thromb Res 1992;6:705-710.
19. Derhaschnig U, Reiter R, Knobl P, Baumgartner M, Keen P, Jilma B. Recombinant human activated protein C (rhAPC, drotrecogin alfa activated) has minimal effect on markers of coagulation, fibrinolysis and inflammation in acute human endotoxemia. Blood 2003;102:2093-2098.
20. Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000;7:2469-2478.
21. Dicker IB, Pedicord DL, Seiffert DA, Jamieson GA, Greco NJ. Both the high affinity thrombin receptor (GPIb-IX-V) and GPIIb/IIIa are implicated in expression of thrombin-induced platelet procoagulant activity. Thromb Haemost 2001;4:1065-1069.
22. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;1:307-315.
23. Bouchard BA, Tracy PB. Platelets, leukocytes, and coagulation. Curr Opin Hematol 2001;5:263-269.
24. Gawaz M, Fateh-Moghadam S, Pilz G, Gurland HJ, Werdan K. Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest 1995;11:843-851.
25. Kirschenbaum LA, Adler D, Astiz ME, Barua RS, Saha D, Rackow EC. Mechanisms of platelet-neutrophil interactions and effects on cell filtration in septic shock. Shock 2002;6:508-512.
26. Kalil AC, Coyle SM, Um JY, LaRosa SP, Turlo MA, Calvano SE, Sundin DP, Nelson DR, Lowry SF. Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004;3:222-229.